CF
CLDX icon

Corebridge Financial’s Celldex Therapeutics CLDX Stock Holding History

Corebridge Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,646
Closed -$574K – 565
2025
Q1 		$574K Sell
31,646
-469
-1% -$10.5K ﹤0.01% 1511
2024
Q4 		$812K Sell
32,115
-2,424
-7% -$65.9K ﹤0.01% 1428
2024
Q3 		$1.17M Sell
34,539
-213
-0.6% -$8.12K 0.01% 1281
2024
Q2 		$1.29M Buy
+34,752
New +$1.31M 0.01% 1207

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's CLDX Position: Q2 2025 in Review

Corebridge Financial sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 31,646 shares — an estimated $574K sold.

Corebridge Financial first reported a position in CLDX in Q2 2024 and held it in 4 quarters. The position peaked at $1.29M in Q2 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Corebridge Financial reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 31,646 Celldex Therapeutics shares in Q2 2025, an estimated $574K.
  • Corebridge Financial first reported a position in Celldex Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Celldex Therapeutics position peaked at $1.29M in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.